Insulet Corporation (NASDAQ:PODD) Holdings Lifted by Allianz Asset Management GmbH

Allianz Asset Management GmbH boosted its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 22.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,016 shares of the medical instruments supplier's stock after buying an additional 25,095 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.20% of Insulet worth $36,507,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Larson Financial Group LLC grew its holdings in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet during the fourth quarter worth about $42,000. Golden State Wealth Management LLC grew its holdings in shares of Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 177 shares during the last quarter. Coppell Advisory Solutions LLC grew its holdings in shares of Insulet by 135.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 162 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after buying an additional 59 shares during the last quarter.

Insulet Trading Down 0.0%

PODD stock traded down $0.09 during midday trading on Thursday, hitting $286.58. The stock had a trading volume of 672,078 shares, compared to its average volume of 576,712. The firm has a market cap of $20.17 billion, a PE ratio of 51.54, a price-to-earnings-growth ratio of 2.56 and a beta of 1.35. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. Insulet Corporation has a 12-month low of $173.00 and a 12-month high of $329.33. The company's 50-day moving average price is $306.37 and its 200 day moving average price is $281.45.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same period in the previous year, the company earned $0.73 EPS. Insulet's revenue for the quarter was up 28.8% on a year-over-year basis. On average, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a report on Tuesday, May 13th. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective for the company. Barclays raised their price objective on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Oppenheimer raised their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research report on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $321.00.

Insider Activity

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president directly owned 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.39% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.